Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.
AUTOR(ES)
Hayden, F G
RESUMO
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=176405Documentos Relacionados
- Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.
- Use of Live Cold-Adapted Influenza A H1N1 and H3N2 Virus Vaccines in Seropositive Adults
- Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.
- Evolution of Swine H3N2 Influenza Viruses in the United States
- Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.
